Navigation Links
PharmaVentures Appoints Andy Smith as Head of Corporate Finance
Date:10/4/2011

OXFORD, England, October 4, 2011 /PRNewswire/ --

PharmaVentures today announced the appointment of Andy Smith as Head of Corporate Finance to significantly enhance Pharmaventures' advisory capabilities and offerings to the global healthcare and investment communities.

Fintan Walton, PhD, PharmaVentures' Chief Executive Office says "We are delighted to welcome Andy to PharmaVentures.  He brings a wealth of investment management experience and has also worked extensively across R&D and marketing in the healthcare sector. At PharmaVentures we are increasingly providing more investment bank style services to help our clients with their dealmaking and Andy's addition to PharmaVentures will therefore be of great benefit."

Andy has a PhD in molecular Biology and an MBA in International Marketing.  He has previously worked with Investment Managers 3i, Schroders Plc and AXA Framlington.  In 2007 he was awarded the techmark Technology Fund Manager of the year.  Since 2011 Andy has written a regular weekly column; Stockwatch, in Scrip and has lectured on healthcare valuations and modeling at the University of Cambridge for the last six years.

PharmaVentures Limited (http://www.pharmaventures.com) is a leading international corporate advisory firm supporting its clients' growth ambitions in the health care industry. It has considerable experience and expertise in the field of tangible and intangible transactions, providing advice at both a strategic level, as well as acting as advisor and broker at an implementation level. Its transactional experience includes licensing, joint ventures, mergers, acquisitions and divestments. Its clients are worldwide, including Europe, the USA and AsiaPacific. Clients range from start-ups to global pharmaceutical corporations, diversified industrial corporations, investment houses and government bodies. Its subsidiary PharmaTelevision produces the highly popular PharmaDeals® range of intelligence products including analysis tools and reports as well as the world's first dedicated online pharmaceutical television channel PharmaTelevision® (http://www.pharmatelevision.com).

Now in its 20th year, PharmaVentures is based in Oxford, UK, and employs over 30 people.


For further information
Fintan Walton, CEO
+44-1865-332733
odette.hodder@pharmaventures.com


'/>"/>
SOURCE PharmaVentures
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. PharmaVentures Engaged by Astex Therapeutics to Assist in the Divestment of US Facility
2. Matrix Corporate Capital and PharmaVentures Announce the Signing of a Memorandum of Understanding (MOU)
3. PharmaVentures Corporate Advisory Appoints Nikki Watkins as Practice Head, Product & Portfolio Strategy
4. PharmaVentures Assists Helsinn in the Successful Sale of Helsinn Chemicals Ireland to the Medinco C.F.M. Group
5. Merck Engages PharmaVentures to Assist in the Divestment of its Italian Research Centre IRBM
6. Redwood Bioscience Appoints Peter Van Vlasselaer, PhD as Executive Chairman
7. PharmAthene Appoints Brian A. Markison to the Companys Board of Directors
8. PrimeraDx Appoints Albert A. Luderer to its Board of Directors
9. Neurologix Appoints Adrian Adams as Company Chairman and Chief Executive Officer
10. Planet Biopharmaceuticals, Inc. Appoints Theron (Ted) Odlaug, Ph.D. as Executive Chairman
11. 3-V Biosciences Appoints George W. Kemble, PhD, as Chief Scientific Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
(Date:6/23/2016)... Calif. , June 23, 2016  The Prostate Cancer Foundation ... increasingly precise treatments and faster cures for prostate cancer. Members of the Class ... across 15 countries. Read More About the Class of ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published today in ... patient who developed lymphedema after being treated for breast cancer benefitted from an injection ... for dealing with this debilitating, frequent side effect of cancer treatment. , ...
Breaking Biology Technology:
(Date:5/16/2016)... --  EyeLock LLC , a market leader of iris-based ... IoT Center of Excellence in Austin, Texas ... embedded iris biometric applications. EyeLock,s iris authentication ... with unmatched biometric accuracy, making it the most proven ... platform uses video technology to deliver a fast and ...
(Date:4/28/2016)... and BANGALORE, India , April 28, ... Systems, a product subsidiary of Infosys (NYSE: INFY ... announced a global partnership that will provide end ... use mobile banking and payment services.      (Logo: ... key innovation area for financial services, but it also plays ...
(Date:4/19/2016)... , UAE, April 20, 2016 ... be implemented as a compact web-based "all-in-one" system solution ... the biometric fingerprint reader or the door interface with ... of modern access control systems. The minimal dimensions of ... ID readers into the building installations offer considerable freedom ...
Breaking Biology News(10 mins):